Pharma Market

Indian pharma market back to pre-Covid level in FY23, says report

After a Covid-hit FY21 (when the IPM grew by only 2.2 per cent), the market posted a growth of 14.7 per cent in FY22, on a low base

Chintan shivir on drugs to diagnose and treat issues of trust, quality

Proposals to be discussed at Hyderabad conclave include having a centralised drug registration system under CDSCO

Pharma marketing practices: High-level committee to meet industry on Friday

The UCPMP is voluntary and there is no legal penalty for violating the code

Centre defends Universal Code of Pharma Marketing Practices in apex court

The government further added that it is working on providing statutory backing to the UCPMP code and "it is a time-consuming process, which cannot be completed in haste"

Expensive deal valuations to hit Torrent Pharma's near-term earnings

Sales trajectory in domestic formulations and resolution of regulatory issues are other triggers

Govt forms 5-member committee to review pharma marketing practices

It will recommend 'legally enforceable mechanisms', is expected to give a report in 90 days

Dr Reddy's Laboratories eyes place among top five domestic pharma players

The US would continue to remain an important geography, but the firm says it hopes to double its revenues from China and grow revenues five-fold in Brazil in the next five years

Domestic branded generic formulations market can grow at 10-12%: Industry

Cadila Healthcare Chairman Pankaj Patel said the market can grow when there is overall growth

Strong growth rates expected to drive Abbott India's outperformance

New launches, power brands, digital initiatives to keep it ahead of peers

Active pharmaceutical ingredients sales momentum begins to normalise

With API supply, especially from China, facing some constraints because of lockdowns in several countries, demand from global clients had shot up for Indian players

Torrent Pharma Q2 net up 27% despite dip in US and Brazil revenues

Firm's consolidated total revenue for the quarter, however, fell marginally by 0.7% to stand at Rs 2,023 crore

Share of drugs under price control dips in domestic pharma market

India follows a market-based mechanism for determining ceiling prices of medicines that are a part of the National List of Essential Medicines (NLEM)

Domestic pharma market bounces back to growth phase in November

The Indian pharma market registered 14.5% YoY growth in November

Post-monsoon Indian pharma market growth slips to 5.1% in October

The drop in growth for the month of October 2019 has been seen across the therapies.

Seven of top 10 drug brands sold in India are from multinational companies

The top 10 corporates contribute to 43% of the domestic pharma market

Will close $150-mn funding in 3-5 months: Medlife CEO Ananth Narayanan

MedLife has seen 100 per cent year-on-year growth. It has built very unique assets that are not there with other players

Our aim is to be a global leader in biosimilars biz: Biocon Biologics CEO

Margins of biologics stood at 38% in Q1 as compared to 33% in the preceding quarter

Pfizer may be talks to merge off-patent drugs business with Mylan

Separation of Pfizer's off-patent business would be a tax-free spin-off

Right prescription

Being highly regulated, brands are wary about being too adventurous online

India's leadership in cost-efficient generics is unchallenged: Sanjiv Kaul

Price erosion has been in excess of 15 per cent last year and will perhaps be at similar levels this year due to sales channel consolidation, says Kaul